Skip Navigation



JAC Advance Access published online on January 31, 2008
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkn026
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
62/2/219    most recent
dkn026v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zhang, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Leading article

Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza

Hong Zhang*

Z-BioMed, Inc., 15725 Crabbs Branch Way, Rockville, MD 20855, USA

* Corresponding author. Tel: +1-301-258-8968; Fax: +1-301-260-0622; E-mail: hzhang{at}zbiomed.com

Sialidase fusion protein is reported to have great potential to combat seasonal and pandemic influenza, because it may prevent influenza virus infection by removing all sialic acid receptors from host cells. Meanwhile, recent studies have demonstrated that absence of {alpha}2-6 sialic acid does not protect a cell from influenza infection, and influenza virus can infect desialylated cells, suggesting that accessible surface sialic acid is dispensable for influenza virus infection. In addition, studies using animal models have shown that neuraminidase promotes adherence and invasion of Streptococcus pneumoniae, because cleavage of sialic acid from host cells exposes cryptic receptors for S. pneumoniae. The purpose of this article is to comment on the benefits and potential risks of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.

Key Words: influenza virus , secondary bacterial pneumonia , animal model


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J.-M. Duez, N. Sixt, and A. Pechinot
Influenza virus infection: don't forget the role of the mucociliary system!
J. Antimicrob. Chemother., February 1, 2009; 63(2): 421 - 422.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. M. Nicholls, L. M. Aschenbrenner, J. C. Paulson, E. R. Campbell, M. P. Malakhov, D. F. Wurtman, M. Yu, and F. Fang
Comment on: Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza
J. Antimicrob. Chemother., August 1, 2008; 62(2): 426 - 428.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. Zhang
Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza--author's response
J. Antimicrob. Chemother., August 1, 2008; 62(2): 428 - 429.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.